GreatBay Bio Showcases AI-Driven Bioprocessing Innovations at Elite Global Inno Day Amid IPO Filing

Recently, Great Bay Bio was invited by Hong Kong Science Park (HKSTP) to participate in the Elite Global Inno Day event, showcasing its latest innovative achievements in AI-driven bioprocessing and drug development.

▲Mr. Liang Guolong, Co-founder and Chairman of Great Bay Bio

This Elite Global Inno Day brought together entrepreneurs, innovators, and industry leaders from multiple sectors, including life health technology, intelligent manufacturing, advertising technology, insurance technology, logistics, and more, creating a high-level platform for industry exchange and collaboration.As a member of the 2023 Hong Kong Science Park Elite Enterprise Program, Mr. Liang Guolong, Co-founder and Chairman of Great Bay Bio, shared the company's innovative practices in AI-driven bioprocessing and drug development at the event.

▲Mr. Guolong Liang, Co-founder and Chairman of Great Bay Bio, Delivered a Speech

During the event,GBB Showcases Core Technology Platforms AlfaCell (Targeted Integration Cell Line Development Platform) and AlfaMedX (Intelligent Catalog Media), Which Are Reshaping the R&D Model of Biopharmaceuticals, Significantly Enhancing Efficiency and Shortening Development CyclesGBB's innovative technology not only promotes the process optimization of biopharmaceuticals but also provides the industry with a new path to accelerate innovation.

▲Product Display

The appearance at Elite Global Inno Day not only showcased GBB's innovative strength in the AI-empowered bioprocessing field but also reflected the company's commitment toThe Vision of Making Global Bioprocess Development Simpler and More Efficient。In the future, Great Bay Bio will further accelerate its exploration in the field of AI and biotechnology integration, bringing more efficient and higher-quality drug solutions to the global biopharmaceutical industry.

▲On-site Communication

▲ Event Scene Photo

▲Team Photo